参考文献/References:
[1] Cummings SR,San Martin J,McClung MR,et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J].N Engl J Med,2009,361(8):756-765.DOI:10.1056/NEJMoa0809493.
[2] Bone HG,Wagman RB,Brandi ML,et al.10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOM trial and open-label extension[J].Lancet Diabetes Endocrinol,2017,5(7):513-523.DOI:10.1016/S2213-8587(17)30138-9.
[3] Stopeck AT,Fizazi K,Body JJ,et al.Safety of long-term denosumab therapy:results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer[J].Support Care Cancer,2016,24(1):447-455.DOI:10.1007/s00520-015-2904-5.
[4] 王琰,朱丽,杨冰,等.地舒单抗对维持性血液透析患者血钙和骨转换指标的影响[J].中华医学杂志,2023,103(8):594-597.DOI:10.3760/cma.j.cn112137-20220913-01935.
[5] Tsuchiya K,Ishikawa K,Kudo Y,et al.Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab,using quantitative computed tomography:a prospective cohort study[J].Bone Rep,2021,14:101090.DOI:10.1016/j.bonr.2021.101090.
[6] Miller PD,Pannacciulli N,Malouf-Sierra J,et al.Efficacy and safety of denosumab vs.bisphosphonates in postmenopausal women previously treated with oral bisphosphonates[J].Osteoporos Int,2020,31(1):181-191.DOI:10.1007/s00198-019-05233-x.
[7] Bone HG,Bolognese MA,Yuen CK,et al.Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass[J].J Clin Endocrinol Metab,2011,96:972-980.DOI:10.1210/jc.2010-1502.
[8] Cosman F,Huang S,McDermott M,et al.Multiple vertebral fractures after denosumab discontinuation:FREEDOM and FREEDOM extension trials additional post hoc analyses[J].J Bone Miner Res,2022,37(11):2112-2120.DOI:10.1002/jbmr.4705.
[9] Grassi G,Chiodini I,Palmieri S,et al.Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence[J].Eur J Endocrinol,2021,185(3):387-396.DOI:10.1530/EJE-21-0157.
[10] Sølling AS,Harsløf T,Langdahl B.Treatment with zoledronate subsequent to denosumab in osteoporosis:a randomized trial[J].J Bone Miner Res,2020,35(10):1858-1870.DOI:10.1002/jbmr.4098.
[11] Cosman F,Crittenden DB,Adachi JD,et al.Romosozumab treatment in postmenopausal women with osteoporosis[J].N Engl J Med,2016,375(16):1532-1543.DOI:10.1056/NEJMoa1607948.
[12] Saag KG,Petersen J,Brandi ML,et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.DOI:10.1056/NEJMoa1708322.
[13] Kobayakawa T,Suzuki T,Nakano M,et al.Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients:a prospective cohort study[J].Bone Rep,2021,14:101068.DOI:10.1016/j.bonr.2021.101068.
[14] Tominaga A,Wada K,Okazaki K,et al.Early clinical effects,safety,and predictors of the effects of romosozumab treatment in osteoporosis patients:one-year study[J].Osteoporos Int,2021,32(10):1999-2009.DOI:10.1007/s00198-021-05925-3.
[15] Bovijn J,Krebs K,Chen CY,et al.Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics[J].Sci Transl Med,2020,12(549):eaay6570.DOI:10.1126/scitranslmed.aay6570.
[16] Lv F,Cai X,Yang W,et al.Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis:systematic review and meta- analysis[J].Bone,2020,130:115121.DOI:10.1016/j.bone.2019.115121.
[17] Kobayakawa T,Miyazaki A,Kanayama Y,et al.Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration[J].Mod Rheumatol,2023,33(1):96-103.DOI:10.1093/mr/roac014.
[18] Kobayakawa T,Miyazaki A,Saito M,et al.Denosumab versus romosozumab for postmenopausal osteoporosis treatment[J].Sci Rep,2021,11(1):11801.DOI:10.1038/s41598-021-91248-6.
[19] Kaveh S,Hosseinifard H,Ghadimi N,et al.Efficacy and safety of Romosozumab in treatment for low bone mineral density:a systematic review and meta-analysis[J].Clin Rheumatol,2020,39(11):3261-3276.DOI:10.1007/s10067-020-04948-1.
[20] Tian A,Jia H,Zhu S,et al.Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis:a systematic review and meta-analysis through a grade analysis of evidence[J].Orthop Surg,2021,13(7):1941-1950.DOI:10.1111/os.13136.
[21] Ebina K,Etani Y,Tsuboi H,et al.Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis[J].Osteoporos Int,2022,3(8):1807-1813.DOI:10.1007/s00198-022-06386-y.
[22] Tominaga A,Wada K,Okazaki K,et al.Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment[J].Osteoporos Int,2022,33(6):1265-1273.DOI:10.1007/s00198-021-06261-2.
[23] Kobayakawa T,Miyazaki A,Takahashi J,et al.Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy:the prospective VICTOR study[J].Bone,2022,162:116480.DOI:10.1016/j.bone.2022.116480.
[24] Brown JP,Engelke K,Keaveny TM,et al.Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women:results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk(ARCH)trial[J].J Bone Miner Res,2021,36(11):2139-2152.DOI:10.1002/jbmr.4409.
[25] McCloskey EV,Johansson H,Harvey NC,et al.Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk:a post hoc analysis of the first year of the frame study[J].Osteoporos Int,2021,32(8):1601-1608.DOI:10.1007/s00198-020-05815-0.
相似文献/References:
[1]齐保玉,魏戌,朱立国,等.血管生成在骨代谢及骨质疏松症中的作用研究进展[J].国际内分泌代谢杂志,2021,41(02):128.[doi:10.3760/cma.j.cn121383-20200326-03066]
Qi Baoyu,Wei Xu,Zhu Liguo,et al.Research progress on the role of angiogenesis in bone metabolism and osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(04):128.[doi:10.3760/cma.j.cn121383-20200326-03066]
[2]杨婷,岳月仪,范雨佳,等.WISP1与骨质疏松症关系的研究进展[J].国际内分泌代谢杂志,2021,41(03):224.[doi:10.3760/cma.j.cn121383-20200417-04051]
Yang Ting,Yue Yueyi,Fan Yujia,et al.Research progress on the relationship between WISP1 and osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(04):224.[doi:10.3760/cma.j.cn121383-20200417-04051]
[3]杨泓娟,龚恬,项守奎.皮肤与骨质疏松症[J].国际内分泌代谢杂志,2024,44(03):202.[doi:10.3760/cma.j.cn121383-20230830-08074]
Yang Hongjuan,Gong Tian,Xiang Shoukui..Skin and Osteoporosis[J].International Journal of Endocrinology and Metabolism,2024,44(04):202.[doi:10.3760/cma.j.cn121383-20230830-08074]